{"title":"Dynamic changes and roles of LYVE-1 during lipopolysaccharide-induced ALI/ARDS in mice","authors":"Shuntaro Matsunaga, Shinnosuke Takamori, Shen Lin, Chen Man, Yukie Mizuta, Sayoko Narahara, Takahito Kawano, Masaharu Murata, Tomohiko Akahoshi","doi":"10.1016/j.bbadva.2026.100202","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) has been recognized as a marker of lymphatic vessels; however, recent studies have reported that LYVE-1 is expressed in diverse cell types and functionally contributes to organ repair. Herein, we examined the expression pattern of LYVE-1 in acute respiratory distress syndrome (ARDS) model mice.</div></div><div><h3>Methods</h3><div>Acute lung injury (ALI) was induced by intratracheal administration of lipopolysaccharide (LPS) in mice. The expression and localization of LYVE-1 during the inflammatory and resolution phases were assessed by immunohistochemistry and western blot analysis. We also assessed the extent of lung injury following pharmacological inhibition of LYVE-1.</div></div><div><h3>Results</h3><div>During the inflammatory phase of lung injury, 6 h after LPS treatment, a marked decrease in LYVE-1 expression was observed, accompanied by the accumulation of hyaluronan in the tissue. During the repair process at 12 and 24 h, LYVE-1 expression transiently increased beyond baseline levels before returning to a steady state. Notably, LYVE-1-positive M2 macrophages were detected during the resolution phase. Furthermore, LYVE-1 inhibition exacerbated the severity of lung injury and resulted in poor prognosis.</div></div><div><h3>Conclusion</h3><div>LYVE-1 exhibits dynamic expression during lung inflammation and repair, not only in lung tissues but also in M2-like macrophages. Therefore, LYVE-1 may serve as a target for future pharmacological interventions in ALI.</div></div>","PeriodicalId":34672,"journal":{"name":"BBA Advances","volume":"10 ","pages":"Article 100202"},"PeriodicalIF":4.5000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13560032/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BBA Advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667160326000232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) has been recognized as a marker of lymphatic vessels; however, recent studies have reported that LYVE-1 is expressed in diverse cell types and functionally contributes to organ repair. Herein, we examined the expression pattern of LYVE-1 in acute respiratory distress syndrome (ARDS) model mice.
Methods
Acute lung injury (ALI) was induced by intratracheal administration of lipopolysaccharide (LPS) in mice. The expression and localization of LYVE-1 during the inflammatory and resolution phases were assessed by immunohistochemistry and western blot analysis. We also assessed the extent of lung injury following pharmacological inhibition of LYVE-1.
Results
During the inflammatory phase of lung injury, 6 h after LPS treatment, a marked decrease in LYVE-1 expression was observed, accompanied by the accumulation of hyaluronan in the tissue. During the repair process at 12 and 24 h, LYVE-1 expression transiently increased beyond baseline levels before returning to a steady state. Notably, LYVE-1-positive M2 macrophages were detected during the resolution phase. Furthermore, LYVE-1 inhibition exacerbated the severity of lung injury and resulted in poor prognosis.
Conclusion
LYVE-1 exhibits dynamic expression during lung inflammation and repair, not only in lung tissues but also in M2-like macrophages. Therefore, LYVE-1 may serve as a target for future pharmacological interventions in ALI.